XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | |
---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | |||||||
Cash flow from continuing operating activities | -465.84%-34.51M | -62.84%3.07M | -150.11%-14.04M | 9.43M | 8.27M | -20.44%28.01M | 35.21M |
Net income from continuing operations | 68.74%-39.89M | -121.01%-16.13M | -1,675.65%-52.28M | ---127.62M | --76.77M | -81.51%3.32M | --17.94M |
Operating gains losses | --95K | 1,200.00%39K | 118.18%2K | --0 | --3K | 42.11%-11K | ---19K |
Depreciation and amortization | 14.57%8.85M | 10.05%8.47M | 92.42%31.67M | --7.72M | --7.69M | 89.28%16.46M | --8.7M |
Deferred tax | 39.14%-678K | 56.45%-2.22M | 61.84%-5.78M | ---1.11M | ---5.11M | -467.39%-15.14M | ---2.67M |
Other non cash items | 116.61%1.9M | 102.24%1.92M | -1,900.80%-109.92M | ---11.43M | ---85.81M | 397.07%6.1M | --1.23M |
Change In working capital | -147.69%-5.49M | -42.29%8.51M | -150.53%-8.74M | --11.52M | --14.75M | 81.46%17.3M | --9.54M |
-Change in receivables | 255.03%2.51M | -322.07%-5.39M | 1,045.01%5.96M | ---1.62M | --2.43M | -105.39%-631K | --11.7M |
-Change in prepaid assets | 58.52%-56K | -160.30%-565K | 186.45%2.3M | ---135K | --937K | -131.22%-2.66M | --8.51M |
-Change in payables and accrued expense | -277.71%-14.41M | -19.24%6.29M | -126.88%-4.79M | --8.11M | --7.78M | 77,543.48%17.81M | ---23K |
-Change in other current liabilities | -251.20%-1.75M | -59.00%-989K | -110.88%-3.33M | ---498K | ---622K | -9.03%-1.58M | ---1.45M |
-Change in other working capital | 44.85%8.21M | 117.32%9.17M | -303.76%-8.88M | --5.67M | --4.22M | 147.38%4.36M | ---9.2M |
Cash from discontinued investing activities | |||||||
Operating cash flow | -465.84%-34.51M | -62.84%3.07M | -150.11%-14.04M | --9.43M | --8.27M | -20.44%28.01M | --35.21M |
Investing cash flow | |||||||
Cash flow from continuing investing activities | -2.96%-1.88M | -30.58%-1.77M | 84.00%-57.19M | -1.83M | -1.36M | -522.10%-357.46M | -57.46M |
Net PPE purchase and sale | 35.10%-159K | -130.43%-106K | -526.88%-2.59M | ---245K | ---46K | -36.75%-413K | ---302K |
Net intangibles purchase and sale | -8.86%-1.72M | -27.08%-1.67M | -129.45%-6.77M | ---1.58M | ---1.31M | -717.45%-2.95M | ---361K |
Net business purchase and sale | ---- | ---- | 86.49%-47.83M | ---- | ---- | -523.44%-354.09M | ---56.8M |
Cash from discontinued investing activities | |||||||
Investing cash flow | -2.96%-1.88M | -30.58%-1.77M | 84.00%-57.19M | ---1.83M | ---1.36M | -522.10%-357.46M | ---57.46M |
Financing cash flow | |||||||
Cash flow from continuing financing activities | 558.32%35.01M | 69.11%-2.42M | -77.50%74.96M | -7.64M | -7.85M | 1,335.26%333.12M | 23.21M |
Net issuance payments of debt | ---- | ---- | --0 | ---- | ---- | 265.00%206.91M | --56.69M |
Net other financing activities | 558.32%35.01M | 69.11%-2.42M | -40.61%74.96M | ---7.64M | ---7.85M | 477.01%126.21M | ---33.48M |
Cash from discontinued financing activities | |||||||
Financing cash flow | 558.32%35.01M | 69.11%-2.42M | -77.50%74.96M | ---7.64M | ---7.85M | 1,335.26%333.12M | --23.21M |
Net cash flow | |||||||
Beginning cash position | 55.77%9.45M | 51.06%10.79M | 94.82%7.14M | --6.07M | --7.14M | 26.46%3.67M | --2.9M |
Current changes in cash | -4,358.06%-1.38M | -19.83%-1.12M | 1.50%3.73M | ---31K | ---938K | 283.52%3.68M | --959K |
Effect of exchange rate changes | 139.05%66K | -56.62%-213K | 57.43%-86K | ---169K | ---136K | -5.21%-202K | ---192K |
End cash Position | 38.65%8.14M | 55.77%9.45M | 51.06%10.79M | --5.87M | --6.07M | 94.82%7.14M | --3.67M |
Free cash flow | -578.35%-36.39M | -81.18%1.3M | -194.92%-23.4M | --7.61M | --6.91M | -28.65%24.65M | --34.55M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD |
Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | Unqualified Opinion with Explanatory Notes | Unqualified Opinion with Explanatory Notes |